Fred E. Cohen is Director at GENOMIC HEALTH INC (GHDX). They have made 10 open-market trades across 4 companies since 2017, most recently 2026-06-12.
CIK 0001339358
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.4M since 2026, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CDNA | 165,060 | $10.6M |
| GHDX | 69,120 | $4.4M |
| NTLA | 216,653 | $2.5M |
| URGN | 69,339 | $2.4M |
| BCRX | 173,660 | $1.4M |
| PGNY | 22,693 | $610K |
| VCYT | 10,000 | $432K |
| FPRX | 8,242 | $313K |
| KYTX | 21,727 |
Shares reported on the most recent Form 4, priced at the 2026-06-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | BUY | 2026-01-05 | 2026-01-07 | $9.35 | $1.4M | +19.7% | +14.6% | +26.5% |
| VCYT | SELL | 2020-05-18 | 2020-05-19 | $26.86 | $2.1M | +0.1% | -0.0% | +34.1% |
| GHDX | SELL | 2019-02-22 | 2019-02-26 | $78.85 | $1.6M | -5.2% | -10.8% | -29.8% |
| GHDX | SELL | 2018-11-08 | 2018-11-13 | $87.67 | $1.3M | -2.4% | -8.1% | +5.7% |
| GHDX | SELL | 2018-09-06 | 2018-09-10 | $61.51 | $1.0M | +6.6% | -2.4% | +14.6% |
| GHDX | SELL | 2018-08-07 | 2018-08-09 | $56.22 | $464K | +3.3% | +16.4% | +64.2% |
| BCRX | SELL | 2017-09-18 | 2017-09-20 | $5.42 | $294K | -3.8% | -13.4% | -9.6% |
| GHDX | SELL | 2017-05-19 | 2017-05-23 | $29.54 | $244K | +10.3% | +14.1% | +1.3% |
| GHDX | SELL | 2017-05-18 | 2017-05-22 | $29.88 | $493K | +10.2% | +12.7% | +0.1% |
| GHDX | SELL | 2017-05-16 | 2017-05-18 | $30.68 | $253K | +6.3% | +8.1% | +1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| $123K |
| Total | $22.7M |